Napo pharmaceuticals, a jaguar health family company, reports completion of last patient last visit for its pivotal phase 3 ontarget trial of crofelemer for preventive treatment of cancer therapy-related diarrhea

Company on track to report top line data in late october 2023 san francisco, ca / accesswire / august 17, 2023 / napo pharmaceuticals (napo), a jaguar health, inc. (nasdaq:jagx) family company, today announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of napo's pivotal phase 3 ontarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. this trial is studying an indication napo also refers to as preventive treatment of chemotherapy-induced overactive bowel (ciob) - which includes symptoms such as chronic debilitating diarrhea (loose and/or watery stools), urgency, and bowel incontinence.
JAGX Ratings Summary
JAGX Quant Ranking